| Revenue Growth | Domestic grew 21% to $657M; International grew 4x to $233M. |
|---|---|
| Mgmt Confidence | High confidence in long-term arc despite near-term subscriber and margin volatility. |
| Demand Visibility | Record first-half additions; record interest in Wegovy pill and Lily partnership. |
| Margin Trends | Gross margins fell 7 points to 57% due to lower-margin branded products. |
| Op. Leverage | Marketing improved 7 points to 28% of revenue; G&A improved 5 points. |
| Pricing Power | Strategic pricing initiatives in UK/Germany; passing efficiencies back as lower prices. |
| Vol vs Price | Growth driven by higher price-point branded offerings despite sequential subscriber decline. |
| Segment Growth | Hers approaching $1B; Testosterone reaching $100M run rate; International scaling rapidly. |
| New Clients | Partnerships with Eli Lilly (Zepbound) and Novo Nordisk (Wegovy) expanded assortment. |
| Capex & Debt | $710M cash/investments; $26M free cash flow; Eucalyptus acquisition integration complete. |
| Regulatory | Monitoring FDA/HHS peptide rulings for BPC 157 and TB 500 launches. |
| Commentary | Prioritizing long-term platform value and customer relationships over near-term subscriber metrics. |
| New Launches | Injectable TRT launched; Peptides Plus (Sermorelin, NAD+) launching end of month. |
Growth
Revenue grew 49% year-over-year to $890 million; International revenue more than 4x to $233 million.
Outlook
Tightened 2026 revenue guidance to $3.13-$3.15 billion; International run rate $1 billion by 2027.
Risks
Sequential decline of 100,000 subscribers and 7-point gross margin drop to 57% due to mix shift.
The company's earnings call, NYSE: HIMS, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Hims & Hers Health, Inc.: key numbers
- Share price
- $18.56Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Services-Offices & Clinics of Doctors of MedicineSIC 8011
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Hims & Hers Health, Inc.
All →Hims & Hers Health Q3 2026 Results: Net Loss of $33M
Hims & Hers Health, Inc. reported a net loss of $33.0 million for the third quarter of 2026, a significant decline from a net income of $15.8 million in the prior year period, despite revenue growing to $890.4 million. The company's balance sheet shows a substantial increase in goodwill and intangible assets, reflecting significant acquisition activity during the first nine months of the year.
- Key figure
- Net loss $33M
Hims & Hers Health Leadership Change
Hims & Hers Health, Inc. increased its board size to ten and appointed Dr. Andrew Huberman as a director, effective November 4, 2026. Alongside his board role, Dr. Huberman entered into a brand marketing and advisory agreement worth $3.5 million annually, while his media company, Scicomm Media LLC, secured a $5 million annual podcast advertising contract.
- Counterparty
- Dr. Andrew Huberman
- Term
- through 2027 annual meeting
Hims & Hers Health Financial Results
Hims & Hers Health reported Q3 2026 revenue of $890.4 million, a 49% year-over-year increase driven by significant international growth and a 13% rise in subscribers to 2.8 million. The company reported a net loss of $33.0 million compared to a profit in the prior year, while tightening its full-year revenue guidance and reducing its Adjusted EBITDA outlook.
- Term
- Q3 2026
“In healthcare, whoever owns the customer relationship wins, and that’s exactly what we’re building toward at Hims & Hers. Today, customers want real choice, real value, and a care team that knows them.”
Andrew Dudum, co-founder and CEO
“In the third quarter, we continued to apply what we’ve learned to make deliberate strategic decisions to position Hims & Hers for durable, multi-year growth.”
Yemi Okupe, Chief Financial Officer
Hims & Hers Health CLO Soleil Boughton Sells $95.6K of Stock
Soleil Boughton, CLO, sold 3,462 shares of Hims & Hers Health, Inc. at $27.60 a share, worth $95.6K in total on Oct 28, 2026. Shares held after the trade: 293,886 (-1.2%).
- Value
- $95.6K
- Shares
- 3,462
- Price
- $27.60
- Role
- CLO
- Holding change
- -1.2%
- Trade date
- Oct 28, 2026
Hims & Hers Health CLO Soleil Boughton Sells $101K of Stock
Soleil Boughton, CLO, sold 3,461 shares of Hims & Hers Health, Inc. at $29.06 a share, worth $101K in total on Oct 14, 2026. Shares held after the trade: 297,348 (-1.2%).
- Value
- $101K
- Shares
- 3,461
- Price
- $29.06
- Role
- CLO
- Holding change
- -1.2%
- Trade date
- Oct 14, 2026
Hims & Hers Health Executive Compensation
Hims & Hers Health, Inc. appointed Jonathan M. Franklin as Chief Accounting Officer and Principal Accounting Officer, effective October 9, 2026. Mr. Franklin's compensation package includes a $425,000 base salary, a $150,000 signing bonus, and $3,000,000 in restricted stock units. He succeeds Irene Becklund, who is transitioning to an advisory role through July 2027.